The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine

Rubinstein, Ethan; Predy, Gerald; Sauv, Laura; Hammond, Greg W.; Aoki, Fred; Sikora, Chris; Li, Yan; Law, Barbara; Halperin, Scott; Scheifele, David
September 2011
CMAJ: Canadian Medical Association Journal;9/20/2011, Vol. 183 Issue 13, pE1033
Academic Journal
Background: Because many Aboriginal Canadians had severe cases of pandemic (H1N1) 2009 influenza, they were given priority access to vaccine. However, it was not known if the single recommended dose would adequately protect people at high risk, prompting our study to assess responses to the vaccine among Aboriginal Canadians. Methods: We enrolled First Nations and Metis adults aged 20--59 years in our prospective cohort study. Participants were given one 0.5-mL dose of ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmith-Kline Canada). Blood samples were taken at baseline and 21--28 days after vaccination. Paired sera were tested for hemagglutinationinhibiting antibodies at a reference laboratory. To assess vaccine safety, we monitored the injection site symptoms of each participant for seven days. We also monitored patients for general symptoms within 7 days of vaccination and any use of the health care system for 21--28 days after vaccination. Results: We enrolled 138 participants in the study (95 First Nations, 43 Metis), 137 of whom provided all safety data and 136 of whom provided both blood samples. First Nations and Metis participants had similar characteristics, including high rates of chronic health conditions (74.4%--76.8%). Pre-existing antibody to the virus was detected in 34.3% of the participants, all of whom boosted strongly with vaccination (seroprotection rate [titre ≥ 40] 100%, geometric mean titre 53--.667). Participants with no pre -existing antibody also responded well. Fifty-eight of 59 (98.3%) First Nations participants showed seroprotection and a geometric mean titre of 353.6; all 30 Metis participants with no pre-existing antibody showed seroprotection and a geometric mean titre of 376.2. Pain at the injection site and general symptoms frequently occurred but were shortlived and generally not severe, although three participants (2.2%) sought medical attention for general symptoms. Interpretation: First Nations and Metis adults responded robustly to ASO3-adjuvanted pandemic (H1N1) 2009 vaccine. Virtually all participants showed protective titres, including those with chronic health conditions. Trial registration: ClinicalTrials.gov trial register no. NCT.01001026.


Related Articles

  • Healthcare Worker Acceptance of Pandemic (H1N1) 2009 Vaccination, Morocco. Tagajdid, Rida; El Annaz, Hicham; Doblali, Taoufik; Sefiani, Kawtar; Belfquih, Bouchra; Mrani, Saad // Emerging Infectious Diseases;Oct2010, Vol. 16 Issue 10, p1638 

    A letter to the editor is presented about a survey of healthcare workers on the acceptance of pandemic H1N1 2009 vaccination in Morocco conducted from January 15 to February 28, 2010.

  • Determinants of adults' intention to vaccinate against pandemic swine flu. Myers, Lynn B.; Goodwin, Robin // BMC Public Health;2011, Vol. 11 Issue 1, p1 

    Background: Vaccination is one of the cornerstones of controlling an influenza pandemic. To optimise vaccination rates in the general population, ways of identifying determinants that influence decisions to have or not to have a vaccination need to be understood. Therefore, this study aimed to...

  • Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. Coleman, B.; Kuster, S.; Gubbay, J.; Scheifele, D.; Li, Y.; Low, D.; Crowcroft, N.; Mazzulli, T.; Shi, L.; Halperin, S.; Law, B.; McGeer, A. // European Journal of Clinical Microbiology & Infectious Diseases;Apr2012, Vol. 31 Issue 4, p591 

    We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20-60 years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875 μg of...

  • Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States. Prosser, Lisa A.; Lavelle, Tara A.; Fiore, Anthony E.; Bridges, Carolyn B.; Reed, Carrie; Jain, Seema; Dunham, Kelly M.; Meltzer, Martin I. // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Background: Pandemic influenza A(H1N1) (pH1N1) was first identified in North America in April 2009. Vaccination against pH1N1 commenced in the U.S. in October 2009 and continued through January 2010. The objective of this study was to evaluate the cost-effectiveness of pH1N1 vaccination....

  • Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination Ioannidis, John P. A.; Manzoli, Lamberto; De Vito, Corrado; D'Addario, Maddalena; Villari, Paolo // PLoS Clinical Trials;Dec2011, Vol. 6 Issue 12, p1 

    Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among...

  • Vical gets good H1N1 pandemic FLU Vaccine Phase 1.  // Biotech Business;Jun2011, Vol. 24 Issue 6, p7 

    The article discusses the favorable Phase 1 trial of Vical Incorporated's Vaxfectin (R)-formulated vaccine for H1N1 pandemic influenza. It reports that the vaccine generated neutralizing antibodies demonstrating its safety and immunogenicity in humans. Information presented states that the trial...

  • Factors associated with parental acceptance and refusal of pandemic influenza A/H1N1 vaccine in Turkey. Akıs, Sule; Velıpasaoglu, Sevtap; Camurdan, Aysu; Beyazova, Ufuk; Sahın, Figen; Akis, Sule; Velipasaoglu, Sevtap; Camurdan, Aysu Duyan; Sahn, Figen // European Journal of Pediatrics;Sep2011, Vol. 170 Issue 9, p1165 

    The objective of this study was to investigate the parents' attitudes towards and identify the possible factors associated with pandemic H1N1 vaccine uptake that was recommended to children between 6 months and 5 years of age. A questionnaire exploring the attitudes of parents to H1N1 vaccine...

  • 2009 H1N1 Vaccination in Minnesota. MUSCOPLAT, MIRIAM HALSTEAD; RODDY, MARGARET; PARILLA, ELIZABETH; DAVEY, CYNTHIA S.; FLEEGE, LAURA; WHITE, KAREN; EHRESMANN, KRISTEN // Minnesota Medicine;Sep2013, Vol. 96 Issue 9, p49 

    According to Minnesota Immunization Information Connection (MIIC) data, 23% of Minnesotans were vaccinated against 2009 pandemic H1N1 influenza. We analyzed 2009 H1N1 vaccination data at the ZIP code level to learn more about who received the vaccine between 2009 and 2010. We found significant...

  • Trust in medical organizations predicts pandemic (H1N1) 2009 vaccination behavior and perceived efficacy of protection measures in the Swiss public. Gilles, Ingrid; Bangerter, Adrian; Clémence, Alain; Green, Eva; Krings, Franciska; Staerklé, Christian; Wagner-Egger, Pascal // European Journal of Epidemiology; 

    Following the recent avian influenza and pandemic (H1N1) 2009 outbreaks, public trust in medical and political authorities is emerging as a new predictor of compliance with officially recommended protection measures. In a two-wave longitudinal survey of adults in French-speaking Switzerland,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics